Handelsbanken Fonder AB Has $112.93 Million Stock Holdings in Stryker Corporation $SYK

Handelsbanken Fonder AB increased its position in shares of Stryker Corporation (NYSE:SYK) by 7.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 285,442 shares of the medical technology company’s stock after buying an additional 20,149 shares during the quarter. Handelsbanken Fonder AB owned about 0.07% of Stryker worth $112,929,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Consolidated Portfolio Review Corp lifted its holdings in shares of Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after purchasing an additional 26 shares in the last quarter. Princeton Global Asset Management LLC increased its stake in Stryker by 16.9% during the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after purchasing an additional 26 shares in the last quarter. Sunflower Bank N.A. raised its holdings in Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after buying an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC lifted its stake in shares of Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after buying an additional 27 shares in the last quarter. Finally, Sachetta LLC grew its holdings in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This represents a 40.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 522,618 shares of company stock valued at $185,577,237 in the last three months. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Needham & Company LLC reissued a “buy” rating and set a $448.00 price objective on shares of Stryker in a report on Friday, November 14th. BTIG Research restated a “buy” rating and issued a $410.00 target price on shares of Stryker in a report on Friday, November 14th. Royal Bank Of Canada reiterated an “outperform” rating and set a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Finally, Wells Fargo & Company increased their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $434.37.

Stryker Stock Down 1.0%

SYK stock opened at $360.46 on Friday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The stock has a market cap of $137.85 billion, a P/E ratio of 47.74, a P/E/G ratio of 2.66 and a beta of 0.94. The stock’s fifty day simple moving average is $369.68 and its two-hundred day simple moving average is $380.77. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.